Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

LYRA

Lyra Therapeutics Inc

Nov 17 • 04:00PM ET

3.74

-0.11 -2.86 %

Healthcare • Biotechnology • USA • NASD

Peers: JNJ PFE MRK GSK BMY LLY REGN AMGN VRTX ALNY

| Held by: VTI VXF DFAS

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-23.78	Insider Own	8.53%	Shs Outstand	1.64M	Perf Week	-15.19%
Market Cap	6.64M	Forward P/E	-	EPS next Y	-4.76	Insider Trans	-43.92%	Shs Float	1.62M	Perf Month	-45.81%
Enterprise Value	15.97M	PEG	-	EPS next Q	-3.76	Inst Own	20.19%	Short Float	1.44%	Perf Quarter	-47.25%
Income	-32.95M	P/S	11.07	EPS this Y	82.09%	Inst Trans	1.88%	Short Ratio	0.78	Perf Half Y	-30.03%
Sales	0.60M	P/B	-	EPS next Y	62.86%	ROA	-53.81%	Short Interest	0.02M	Perf YTD	-63.76%
Book/sh	-2.63	P/C	0.30	EPS next 5Y	54.56%	ROE	-404.48%	52W High	37.50 -90.03%	Perf Year	-62.16%
Cash/sh	12.42	P/FCF	-	EPS past 3/5Y	24.62% -2.22%	ROIC	-147.30%	52W Low	3.69 1.36%	Perf 3Y	-97.81%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	75.25% -	Gross Margin	3.50%	Volatility	8.84% 8.25%	Perf 5Y	-99.31%
Dividend TTM	-	EV/Sales	26.62	EPS Y/Y TTM	68.97%	Oper. Margin	-5401.33%	ATR (14)	0.46	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	2.43	Sales Y/Y TTM	-59.21%	Profit Margin	-5491.17%	RSI (14)	20.29	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.43	EPS Q/Q	62.68%	SMA20	-28.94%	Beta	0.03	Target Price	11.50
Payout	-	Debt/Eq	-	Sales Q/Q	-87.18%	SMA50	-39.94%	Rel Volume	0.55	Prev Close	3.85
Employees	30	LT Debt/Eq	-	Earnings	Nov 12 AMC	SMA200	-52.02%	Avg Volume	30.09K	Price	3.74
IPO	May 01, 2020	Option/Short	No / Yes	EPS/Sales Surpr.	35.68% -87.85%	Trades		Volume	16,562	Change	-2.86%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Downgrade	Jefferies	Buy → Hold	$10 → $0.50
May-07-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $2
May-07-24	Downgrade	BofA Securities	Buy → Underperform
May-06-24	Downgrade	William Blair	Outperform → Mkt Perform
Oct-06-23	Resumed	BTIG Research	Buy	$15
Aug-31-23	Initiated	H.C. Wainwright	Buy	$12
May-24-22	Initiated	Cantor Fitzgerald	Overweight	$15
May-26-20	Initiated	William Blair	Outperform
May-26-20	Initiated	Jefferies	Buy	$24
May-26-20	Initiated	BTIG Research	Buy	$28
May-26-20	Initiated	BofA/Merrill	Buy	$21

Show Previous Ratings

Nov-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -8.49%
04:01PM	Lyra Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-10-25 05:45PM	Assertio (ASRT) Surpasses Q3 Earnings and Revenue Estimates (Zacks)
Nov-06-25 09:15AM	Dentsply International (XRAY) Lags Q3 Earnings Estimates (Zacks) -12.81%
Nov-04-25 09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -5.30%
07:00AM	Loading…
Oct-06-25 07:00AM	Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study (GlobeNewswire) +15.57%
Aug-12-25 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Beats Revenue Estimates (Zacks) +8.00%
04:01PM	Lyra Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Aug-08-25 08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
Jun-27-25 08:00AM	Lyra Therapeutics Announces Up to Approximately $15 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -31.91%
Jun-12-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Buy: Here's Why (Zacks) -12.22%
Jun-05-25 12:55PM	Lyra Stock Soars 356% in a Week on Strong Rhinosinusitis Study Success (Zacks) +11.00%
Jun-02-25 12:08PM	Lyra Therapeutics Shares Climb Over 500% After Major CRS Trial Win (GuruFocus.com) +310.75%
07:00AM	Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically Significant Results for Primary and Key Secondary Endpoints in the Treatment of Chronic Rhinosinusitis (CRS) (GlobeNewswire)
May-07-25 07:00AM	Lyra Therapeutics to Present 52-week Extension Stage Results for ENLIGHTEN 1 Phase 3 Study for LYR-210 for the Treatment of Chronic Rhinosinusitis at COSM 2025 (GlobeNewswire)
05:20PM	Loading…
May-06-25 05:20PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-31-25 06:55PM	Vivos Therapeutics, Inc. (VVOS) Reports Q4 Loss, Lags Revenue Estimates (Zacks) -9.07%
Mar-13-25 04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jan-09-25 12:00PM	Lyra Therapeutics (LYRA) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
Nov-12-24 05:15PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -28.11%
04:01PM	Lyra Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-15-24 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN 2 Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Sep-27-24 07:00AM	Lyra Therapeutics to Present Study Results for LYR-210 and LYR-220 in Two Presentations at the ARS and AAO-HNS Annual Meetings (GlobeNewswire) +10.07%
Aug-14-24 09:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-15-24 11:35AM	Lyra Therapeutics, Inc. (LYRA): A Good Penny Stock to Buy For Under $1? (Insider Monkey)
May-21-24 10:31AM	Lyra Therapeutics Reduces Workforce to Extend Cash Runway (MT Newswires)
09:14AM	Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital (GlobeNewswire)
09:54AM	Loading…
May-07-24 09:54AM	Target upgraded, CVS downgraded: Wall Street's top analyst calls (The Fly) -19.46%
07:39AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:38AM	--HC Wainwright Downgrades Lyra Therapeutics to Neutral From Buy (MT Newswires)
May-06-24 12:08PM	DJT Stock: Trump Media Fires Accounting Firm, Hires Replacement After SEC Charges (InvestorPlace) -87.06%
11:32AM	ZK Stock IPO: When Does Zeekr Go Public? What Is the Zeekr IPO Price Range? (InvestorPlace)
11:07AM	Warren Buffett Just Gave Up on Paramount (PARA) Stock (InvestorPlace)
10:51AM	Why Is Lyra Therapeutics (LYRA) Stock Down 90% Today? (InvestorPlace)
08:52AM	Lyra Therapeutics Phase 3 Trial of LYR-210 Falls Short of Primary Endpoint, Plans to Cut Staff; Shares Drop Pre-Bell (MT Newswires)
07:59AM	Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Apr-30-24 09:56PM	LYRA Stock Earnings: Lyra Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace) +9.09%
05:30PM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:04PM	Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-26-24 04:51PM	Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -8.70%
Mar-28-24 07:08AM	Lyra Therapeutics (LYRA) Soars 6.5%: Is Further Upside Left in the Stock? (Zacks)
Mar-25-24 08:50AM	Lyra Therapeutics (LYRA) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
Mar-23-24 05:31AM	Lyra Therapeutics Inc (LYRA) Posts Year-End Financial Results, Aligns with EPS Projections (GuruFocus.com)
Mar-22-24 09:55AM	Wall Street Analysts See a 101.81% Upside in Lyra Therapeutics (LYRA): Can the Stock Really Move This High? (Zacks)
Mar-21-24 10:54PM	LYRA Stock Earnings: Lyra Therapeutics Beats EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:01PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-08-24 08:50AM	Here's Why Momentum in Lyra Therapeutics, Inc. (LYRA) Should Keep going (Zacks)
Mar-01-24 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.17%
Feb-26-24 03:58AM	Strength Seen in Lyra Therapeutics, Inc. (LYRA): Can Its 6.9% Jump Turn into More Strength? (Zacks)
Feb-21-24 08:50AM	Here's What Could Help Lyra Therapeutics, Inc. (LYRA) Maintain Its Recent Price Strength (Zacks)
Jan-17-24 08:50AM	What Makes Lyra Therapeutics, Inc. (LYRA) a Good Fit for 'Trend Investing' (Zacks)
Nov-07-23 04:01PM	Lyra Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
07:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-16-23 07:00AM	Lyra Therapeutics Announces Appointment of Ronan O'Brien as Chief Legal Officer (GlobeNewswire)
Sep-13-23 01:22PM	Lyra (LYRA) Posts Upbeat Data on Rhinosinusitis Study, Stock Up (Zacks)
Sep-12-23 07:00AM	Lyra Therapeutics Announces Positive Topline Results from BEACON Phase 2 Study of LYR-220 for the Treatment of Chronic Rhinosinusitis (CRS) in Patients with Prior Ethmoid Sinus Surgery (GlobeNewswire) +7.48%
Sep-06-23 08:00AM	Lyra Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-29-23 07:00AM	Lyra Therapeutics Fully Enrolls Pivotal Phase 3 ENLIGHTEN I Trial of LYR-210 for the Treatment of Chronic Rhinosinusitis (GlobeNewswire)
Aug-08-23 05:50PM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-13-23 07:30AM	Lyra Therapeutics to Present at William Blair Virtual Biotechnology Conference (GlobeNewswire)
Jun-02-23 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.14%
07:30AM	Lyra Therapeutics to Present at Jefferies Healthcare Conference (GlobeNewswire)
Jun-01-23 07:29AM	Lyra Therapeutics Announces Closing of $50.0 Million Private Placement (GlobeNewswire) +5.06%
May-26-23 07:57AM	Lyra Therapeutics Announces $50.0 Million Private Placement (GlobeNewswire) +6.58%
May-14-23 08:19AM	Lyra Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-12-23 08:15AM	Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-09-23 04:01PM	Lyra Therapeutics to Present at Bank of America Securities 2023 Healthcare Conference (GlobeNewswire)
Apr-29-23 08:19AM	Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) biggest owners are retail investors who got richer after stock soared 18% last week (Simply Wall St.)
Apr-25-23 07:59AM	Lyra Therapeutics Announces Restart of Pivotal Phase 3 ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis (GlobeNewswire)
Mar-29-23 04:06PM	Lyra Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-20-23 01:11PM	Estimating The Intrinsic Value Of Lyra Therapeutics, Inc. (NASDAQ:LYRA) (Simply Wall St.)
Mar-01-23 05:21AM	Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock? (Zacks) -5.04%
Feb-28-23 05:17AM	Lyra Therapeutics, Inc. (NASDAQ:LYRA) insiders placed bullish bets worth US$1.5m in the last 12 months (Simply Wall St.)
Feb-27-23 07:59AM	Lyra Therapeutics Announces Appointment of John Bishop, Ph.D., as Chief Technology Officer (GlobeNewswire)
Feb-07-23 01:23PM	Here's Why We're Watching Lyra Therapeutics' (NASDAQ:LYRA) Cash Burn Situation (Simply Wall St.)
Feb-06-23 07:56AM	Lyra Therapeutics Announces Completion of Enrollment in the BEACON Phase 2 Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients (GlobeNewswire)
Jan-17-23 06:42PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-20-22 08:52AM	Further weakness as Lyra Therapeutics (NASDAQ:LYRA) drops 15% this week, taking one-year losses to 49% (Simply Wall St.)
Nov-09-22 08:00AM	Lyra Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) -15.52%
Nov-08-22 05:45PM	Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:01PM	Lyra Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Sep-21-22 06:11AM	Bullish insiders at Lyra Therapeutics, Inc. (NASDAQ:LYRA) loaded up on US$1.5m of stock earlier this year (Simply Wall St.)
Sep-13-22 04:01PM	Lyra Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
07:00AM	Lyra Therapeutics Advances Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients to Randomized Stage of Study (PR Newswire)
Sep-10-22 08:00AM	LYRA THERAPEUTICS announces additional data presentations FROM PHASE 2 LANTERN STUDY at the americal rhinologic society annual meeting (PR Newswire)
Sep-08-22 07:00AM	Lyra Therapeutics Announces First Patient Enrolled in Pivotal ENLIGHTEN II Clinical Trial of LYR-210 in Chronic Rhinosinusitis Patients (PR Newswire)
Sep-06-22 07:00AM	Lyra Therapeutics to Present at the H.C. Wainwright AnnualGlobal Investment Conference 2022 (PR Newswire)
Aug-31-22 02:08PM	We're Hopeful That Lyra Therapeutics (NASDAQ:LYRA) Will Use Its Cash Wisely (Simply Wall St.)
Aug-29-22 07:00AM	Lyra Therapeutics to Present Additional LANTERN Phase 2 Study Results for LYR210 in Two Oral Presentations at ARS Annual Meeting (PR Newswire) +8.52%
Aug-11-22 08:05AM	Are Institutions Heavily Invested In Lyra Therapeutics, Inc.'s (NASDAQ:LYRA) Shares? (Simply Wall St.)
Aug-09-22 08:25AM	Lyra Therapeutics, Inc. (LYRA) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Lyra Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update (PR Newswire)
Jul-27-22 09:40AM	Has Lyra Therapeutics (LYRA) Outpaced Other Medical Stocks This Year? (Zacks)
Jul-13-22 09:21AM	Increasing losses over year doesn't faze investors as stock rallies 12% this past week (Simply Wall St.)
Jul-05-22 07:00AM	Lyra Therapeutics to Present at the William Blair Biotech Focus Conference 2022 (PR Newswire)

Lyra Therapeutics, Inc. is a clinical-stage therapeutics company. It develops novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases. The firms proprietary XTreo deliver medicines. The company was founded by Carmichael S. Roberts, George M. Whitesides, and Robert S. Langer in November 2005 and is headquartered in Watertown, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 13 '25	Sale	3.90	31,810	124,062	14,026	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 12 '25	Sale	4.06	8,745	35,499	17,239	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 11 '25	Sale	4.31	5,320	22,954	18,122	Nov 13 05:07 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 06 '25	Sale	5.18	32,149	166,529	22,521	Nov 10 05:08 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 07 '25	Sale	4.75	19,739	93,695	20,528	Nov 10 05:08 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Nov 10 '25	Sale	4.54	18,502	83,995	18,659	Nov 10 05:08 PM
Palasis Maria	Officer	Oct 14 '25	Proposed Sale	7.23	537	3,881		Oct 14 03:09 PM
Palasis Maria	President & CEO	Jul 10 '25	Sale	8.91	1,565	13,944	1,098,435	Jul 14 09:27 PM
Cavalier Jason	Chief Financial Officer	Jul 10 '25	Sale	8.91	684	6,094	519,316	Jul 14 09:27 PM
Palasis Maria	Officer	Jul 10 '25	Proposed Sale	8.91	1,565	13,945		Jul 10 04:05 PM
Waksal Harlan	Officer	Apr 25 '25	Proposed Sale	0.10	145,370	14,930		Apr 25 03:41 PM
Palasis Maria	Officer	Apr 09 '25	Proposed Sale	0.09	39,567	3,545		Apr 09 03:44 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LYRA

Lyra Therapeutics Inc

Upgrade your FINVIZ experience